Choose from over one hundred high-quality DNA FISH probes for the detection of genetic aberrations found in cancer and inherited genetic diseases.
Discover moreFeaturing the new constitutional NGS platform for cytogenetic research, alongside a broad range of arrays for rare disease and cancer research.
Discover moreChoose from preloaded NGS panels for haematological and solid tumour cancer research or we can help you create your own.
Discover moreThe panel accurately detects SNVs and indels in genes such as CEBPA, JAK2, CALR and MPL, as well as structural variants including FLT3-ITDs and KMT2A-PTDs, and is able to detect low-frequency SNVs and indels with confidence. The figure (right) shows a PTD detection spanning exons 2-8 of the KMT2A gene.
Familial Hypercholesterolaemia (FH) is a genetic condition which results in a high cholesterol level and subsequently leads to a higher risk of early heart disease. OGT is offering an optimised NGS panel which has selected the most relevant genes and SNPs implicated in FH, for your research needs. The figure (left) shows a double deletion on the LDLR gene, as visualised by Interpret software.
The triple colour design of the Del(5q) Plus Tri-Colour Deletion Probe facilitates the detection of 5q interstitial proximal and distal deletions, in addition to monosomy 5 in AML and MDS analysis. The CytoCell CBFB Breakapart Probe, with its dual colour, dual fusion probe design, detects rearrangements in the 16q22 region and overcomes limitations associated with the proximity of signals on chromosome 16 during interphase FISH for AML detection.
We believe that collaboration is key to improving patient lives. By sharing our knowledge and expertise, we ensure that we move forward with our customers, bound by a collective commitment to unlocking the future of genetic clinical care. See our story.
Enhanced NGS portfolio includes Interpret Software updates and enables rapid and confident variant detection even in difficult-to-sequence regions.
ReadExpansion of access to clinical support network and market-leading genomic solutions aims to improve patient outcomes.
ReadNew leadership will drive OGT’s mission to improve clinical care by partnering with customers.
Read
